Журнал "Почки" №2 (20) 2017
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Запрошені статті / Guest Articles<br />
22. Shulman Gerald I. Cellular mechanisms of insulin resistance<br />
// Journal of Clinical Investigation. — <strong>20</strong>00, Jul 15. —<br />
Vol. 106(2). — Р. 171-176. — doi: 10.1172/JC110583.<br />
23. Roith D., Zick Y. Recent advances in our understanding of<br />
insulin action and insulin resistance // Diabetes Care. — <strong>20</strong>01. —<br />
Vol. 24, № 3. — Р. 588-597.<br />
24. Kubo M., Kiyohara Y., Kato I. et al. Effect of hyperinsulinemia<br />
on renal function in a general Japanese population: the<br />
Hisayama study // Kidney International. — 1999. — Vol. 55,<br />
№ 6. — Р. 2450-2456.<br />
25. Sarafidis P.A., Ruilope L.M. Insulin resistance, hyperinsulinemia,<br />
and renal injury: mechanisms and implications //<br />
American Journal of Nephrology. — <strong>20</strong>06. — Vol. 26, № 3. —<br />
Р. 232-244. — doi: org/10.1159/000093632.<br />
26. Perlstein T.S., Gerhard-Herman M., Hollenberg N.K.<br />
et al. Insulin induces renal vasodilation, increases plasma renin<br />
activity, and sensitizes the renal vasculature to angiotensin<br />
receptor blockade in healthy subjects // J. Am. Soc. Nephrol. —<br />
<strong>20</strong>07. — 18. — Р. 944-951. — doi: 10.1681/ASN.<strong>20</strong>06091026.<br />
27. Khamaisi M., Flyvbjerg A., Haramati Z. et al. Effect of<br />
mild hypoinsulinemia on renal hypertrophy: growth hormone/<br />
insulin-like growth factor 1 system in mild streptozotocin diabetes<br />
// Int. J. Exp. Diab. Res. — <strong>20</strong>02. — 3. — Р. 257-264. — doi:<br />
10.1080/15604280290014008.<br />
28. Wang S., De Nichilo M., Brubaker C., Hirschberg R.<br />
Connective tissue growth factor in tubulointerstitial injury of diabetic<br />
nephropathy // Kidney Int. — <strong>20</strong>01. — 60. — Р. 96-105. —<br />
doi: 10.1046/i.1523-1755.<strong>20</strong>01.00776.x.<br />
29. Sowers J.R. Metabolic risk factors and renal disease //<br />
Kidney International. — <strong>20</strong>07. — Vol. 71, № 8. — Р. 719-7<strong>20</strong>. —<br />
http://dx.doi.org/10.1038/si.ki.500<strong>20</strong>06.<br />
30. Villareal D.T., Apovian C.M., Kushner R.F., Klein S.<br />
Obesity in older adults: Technical review and position statement of<br />
the American Society for Nutrition and NAASO, the Obesity Society<br />
// American Journal of Clinical Nutrition. — <strong>20</strong>05. — 82. —<br />
Р. 923-934.<br />
31. Coelho M., Oliveira T., Fernandes R. // Arch. Med.<br />
Sci. — <strong>20</strong>13. — 9. — 2. — Р. 191-<strong>20</strong>0. — doi: 10.5114/<br />
aoms.<strong>20</strong>13.33181.<br />
32. Pan S.Y., Des Meules M., Morrison H., Wen S.W.<br />
Obesity, high energy intake, lack of physical activity, and<br />
the risk of kidney cancer // Cancer Epid. Biom. Prev. —<br />
<strong>20</strong>06. —15. — Р. 2453-60. — doi: 10.1158/1055-9965.EPI-<br />
06-0616.<br />
33. Sivestava T. Nondiabetic consequences of obesity on<br />
kidney // Pediatr. Nephrol. — <strong>20</strong>06. — 21. — Р. 463-70. — doi:<br />
10.1007/s00467-006-0027-4.<br />
34. Rutkowski P., Klasen A., Sebekova K. Renal disease in<br />
obesity. The need for greater attention // J. Ren. Nutr. — <strong>20</strong>06. —<br />
16. — Р. 216-33. — doi: 10.1053/i.im.<strong>20</strong>06.04.017.<br />
35. Chertow G.M., Hsu C., Johansen K.L. The emerging<br />
body of evidence: obesity and chronic kidney disease // J. Am.<br />
Soc. Nephrol. — <strong>20</strong>06. — 17. — Р. 1501-2. — doi: 10.1681/<br />
ASN/<strong>20</strong>06040327.<br />
36. Mathew A.V., Okada S., Sharma K. Obesity related kidney<br />
disease // Curr. Diabetes Rev. — <strong>20</strong>11. — 7. — Р. 41-9.<br />
37. Eknoyan G. Obesity and chronic kidney disease // Nefrologia.<br />
— <strong>20</strong>11. — 31(4). — Р. 397-403. — doi: 10.3265/Nefrologia.pre<strong>20</strong>11.May.10963.<br />
38. Praga M. Obesity — a neglected culprit in renal disease //<br />
Nephrol. Dial. Transpl. — <strong>20</strong>02. —17. — Р. 1157-9.<br />
39. Iseki K., Ikenuya Y., Kinjo K. Body mass index and<br />
the risk of development of end-stage renal disease in a screened<br />
cohort // Kidney Int. — <strong>20</strong>04. — 65. — Р. 1870-9. — doi:<br />
10/1111/i.1523-1755.<strong>20</strong>04.00582.x.<br />
40. Hsu C., McCulloch C.E., Iribarren C., Darbinian J.,<br />
Go A.S. Body mass index and risk for end-stage renal disease //<br />
Ann. Intern. Med. — <strong>20</strong>06. — 144. — Р. 21-8.<br />
41. Sjerblad E., Fored C.M., Lindbald P. Obesity and risk<br />
for chronic renal failure // J. Am. Soc. Nephrol. — <strong>20</strong>06. — 17. —<br />
Р. 1695-702. — doi: 10.1681/ASN.<strong>20</strong>05060638.<br />
42. Praga M., Hernandez E., Morales E., Campos A.P.,<br />
Valero M.A., Martinez M.A. et al. Clinical features and longterm<br />
outcome of obesity-associated focal segmental glomerulosclerosis<br />
// Nephrol. Dial. Transplant. — <strong>20</strong>01. — 16. —<br />
Р. 1790-1798.<br />
43. Jennet J., Olson J., Schwartz M., Silva F. Pathology of<br />
the Kidney // Heptinstall’s. — <strong>20</strong>07. — P. 386.<br />
44. Kambham N., Markowitz G., Valeri A., Lin J., D’Agati V.<br />
Obesity-related glomerulopathy: an emerging epidemic // Kidney<br />
International. — <strong>20</strong>01. — Vol. 59, № 4. — Р. 1498-1509.<br />
45. Myers M.G. Jr, Munzberg H., Leinninger G.M., Leshan<br />
R.L. The geometry of leptin action in the brain:more complicated<br />
than a simple ARC // Cell. Metab. — <strong>20</strong>09. — 9. — Р. 117-<br />
123. — doi: 10.1016/i.cmet.<strong>20</strong>08.12.001.<br />
46. Vanholder R., de Smet R., Glorieux G. et al. Review on<br />
uremic toxins: classification, concentration, and interindividual<br />
variability // Kidney Int. — <strong>20</strong>03. — 63. — Р. 1934-1943.<br />
47. Lee M.C., Lee C.J., Ho G.J. et al. Hyperleptinemia positively<br />
correlated with metabolic syndrome in renal transplant recipients<br />
// Clin. Transplant. — <strong>20</strong>10. — 24. — Р. 124-129.<br />
48. Stenvinkel P., Heimburger O., Lonnqvist F. Serum leptin<br />
concentrations correlate to plasma insulin concentrations independent<br />
of body fat content in chronic renal failure // Nephrol. Dial.<br />
Transplant. — 1997. — 12. — Р. 1321-1325.<br />
49. Bueno de Oliveira R., Liabeuf S., Okazaki H. et al. The<br />
clinical impact of plasma leptin levels in a cohort of chronic kidney<br />
disease patients // Clin. Kidney J. — <strong>20</strong>13. — 6. — Р. 63-70. —<br />
doi: 10.1093/ckj/sfs176.<br />
50. Sowers J.R. Metabolic risk factors and renal disease //<br />
Kidney International. — <strong>20</strong>07. — Vol. 71, № 8. — Р. 719-7<strong>20</strong>. —<br />
http://dx.doi.org/10.1038/si.ki.500<strong>20</strong>06.<br />
51. Savage, D.B., Sewter C.P., Klenk E.S. et al. Resistin/<br />
Fizz3 expression in relation to obesity and peroxisome proliferatoractivated<br />
receptor-γ action in humans // Diabetes. — <strong>20</strong>01. —<br />
50. — Р. 2199-2<strong>20</strong>2.<br />
52. Lee J.H., Chan J.L., Yiannakouris N. et al. Circulating<br />
resistin levels are not associated with obesity or insulin resistance<br />
in humans and are not regulated by fasting or leptin administration:<br />
Cross-sectional and interventional studies in normal,<br />
insulin-resistant, and diabetic subjects // J. Clin. Endocrinol.<br />
Metab. — <strong>20</strong>03. — 88. — Р. 4848-4856. — doi: 10.1210/<br />
ic.<strong>20</strong>03-030519.<br />
53. Won J.C., Park C.Y., Lee W.Y. et al. Association of plasma<br />
levels of resistin with subcutaneous fat mass and markers of<br />
inflammation but not with metabolic determinants or insulin resistance<br />
// J. Korean Med. Sci. — <strong>20</strong>09. — 24. — Р. 695-700. — doi:<br />
10.3346/jkms.<strong>20</strong>09.24.4.695.<br />
<strong>20</strong> Почки, p-ISSN 2307-1257, e-ISSN 2307-1265 Том 6, № 2, <strong>20</strong>17
Change language